EHR-facilitated collaborative care intervention increased initial palliative care consults by 50% in metastatic cancer patients

This study represents a secondary analysis of a cluster-randomized pragmatic trial conducted within a multistate health system. The research population consisted of 16,406 oncology patients diagnosed with metastatic cancer. The study setting involved outpatient care across this extensive health system network. The intervention period spanned from March 2019 to January 2023. The primary focus was on patients with advanced or metastatic cancer who required monitoring and management of SPPADE symptoms. These symptoms include Sleep interference, Pain, impaired Physical function, Anxiety, Depression, and Energy deficit or fatigue. The intervention utilized an EHR-facilitated collaborative care model to address these specific symptom clusters.

The intervention protocol included monthly surveys to track patient-reported symptoms. Automated delivery of symptom self-management tools was provided to patients. Access to symptom care managers was also integrated into the workflow. The comparator group received usual care without these specific EHR-facilitated components. This design allowed for a direct comparison of outcomes between the enhanced care model and standard practice within the same health system infrastructure.

The primary outcome measured was the rate of initial palliative care consults. During the intervention period, the rate of initial PC consults was 50% higher compared with the usual care period. The incidence rate ratio was calculated at 1.50. The statistical significance of this finding was confirmed with a p-value less than 0.001. Absolute numbers for the consult rates were not reported in the available data. The direction of the effect was clearly increased utilization of palliative care services.

Secondary outcomes were not reported in the provided evidence. Safety and tolerability findings were also not reported. There were no reported adverse events, serious adverse events, or discontinuations associated with the intervention. The study limitations included analysis restricted to patients with metastatic disease. This restriction means results may not generalize to patients with earlier-stage cancer or other conditions. The cluster-randomized trial design supports causal inference between the intervention and the observed outcome. However, the certainty of the evidence was not reported in the source data.

These results compare favorably to the need for improved palliative care access in metastatic cancer populations. Prior landmark studies often highlight barriers to early palliative care integration. This intervention demonstrates that EHR-facilitated symptom surveillance and collaborative care management can significantly increase outpatient palliative care utilization. The findings are particularly relevant for health systems managing large metastatic cancer populations. The approach offers a scalable method to identify patients who might otherwise delay seeking palliative care support.

Key methodological limitations include the restriction of the analysis to metastatic disease patients. Potential biases related to cluster randomization were not detailed in the provided text. Funding or conflicts of interest were not reported. The study phase was not reported. Questions remain unanswered regarding long-term sustainability of these consult rates. It is unclear if similar interventions yield comparable results in non-multistate health systems. The lack of reported absolute numbers limits the ability to calculate specific rates or compare directly with other studies using different denominators.

Clinical implications suggest that implementing EHR-facilitated symptom surveillance can be a viable strategy to boost palliative care engagement. Health systems should consider integrating automated symptom self-management and care manager access into their workflows. This approach addresses the SPPADE symptom burden while simultaneously improving care access. Practice decisions should weigh the proven increase in consult rates against the resources required for EHR integration and care manager staffing. The evidence supports the use of this model in outpatient settings for advanced cancer patients.

Unanswered questions include the applicability of these findings to non-metastatic cancer populations. The long-term impact of increased palliative care consults on patient outcomes and quality of life remains to be determined. The specific mechanisms driving the 50% increase in consults warrant further investigation. Future research should explore whether similar interventions are effective in different healthcare settings or with different patient demographics. The lack of safety data means clinicians must monitor for any potential unintended consequences of increased care engagement.